News | Pacemakers | August 29, 2016

One-Year Results for Micra TPS Pacemaker Trial Presented at ESC 2016

Results for world’s smallest pacemaker demonstrate consistent, sustained safety and effectiveness

Medtronic, Micra TPS pacemaker, transcatheter pacing system, global clinical trial, one-year results, ESC 2016

August 29, 2016 — Medtronic plc announced new long-term results from the Medtronic Micra Transcatheter Pacing System (TPS) Global Clinical Trial in a late-breaking session at the 2016 European Society of Cardiology (ESC) Congress. The meeting runs from Aug.27-31 in Rome.

The Micra TPS is less than one-tenth the size of traditional pacemakers and is the only leadless pacemaker approved for use in both the United States and Europe. Data presented at ESC showed that the risk for major complications with the Micra TPS remained consistently low, with 96 percent of patients experiencing no major complications through 12 months follow-up (95 percent CI, 94.2 percent-97.2 percent, P<0.0001). The Micra TPS reduced the risk of major complications by nearly half (48 percent; hazard ratio = 0.52, P=0.001) compared to conventional systems and the risk was lower across all patient sub-groups, whether measured by age, sex or comorbidity (all hazard ratios < 1.0).

The overall reduction in major complications with the Micra TPS was associated with a 47 percent decrease (p=0.017) in the risk of hospitalization and 82 percent (p<0.001) reduction in risk of system revisions (meaning extraction, repositioning or replacement) compared to conventional pacing systems. These reductions were largely due to the elimination of complications such as pneumothoraces (air between the lungs and chest wall), the absence of Micra dislodgements and device infections.

"The Micra TPS has consistently demonstrated strong effectiveness and safety benefits in patients with diverse comorbidities," said Philippe Ritter, M.D., principal investigator of the Micra TPS Global Clinical Trial and cardiologist at University Hospital of Bordeaux in France. "All pre-specified safety and efficacy objectives from the trial were met, with consistent findings from early performance, six- and 12-month data."

Micra battery projections continue to perform in-line with conventional pacemaker systems. Based on 644 patients with 12-month device use conditions available, Micra yielded a projected average longevity of more than 12 years.

In November 2015, preliminary results from the Medtronic Micra TPS Global Clinical Trial were published in the New England Journal of Medicine, which showed the device was successfully implanted in 99.2 percent of patients, and that the system met its safety and effectiveness endpoints with wide margins. The 12-month data presented at ESC continues to reinforce these results, demonstrating consistent and sustained results from early performance through 12-month follow-up.

The device is comparable in size to a large vitamin, yet delivers advanced pacing technology to patients via a minimally invasive approach. During the implant procedure, it is attached to the heart with small tines and delivers electrical impulses that pace the heart through an electrode at the end of the device.

Unlike traditional pacemakers, the Micra TPS does not require leads or a surgical "pocket" under the skin, so potential sources of complications related to such leads and pocket are eliminated — as are any visible signs of the device.

The Micra design also incorporates a retrieval feature to enable retrieval when possible; however, the device is designed to be left in the body. For patients who need more than one device, the miniaturized Micra TPS was designed with a unique feature that enables it to be permanently turned off so it can remain in the body and a new device can be implanted without risk of electrical interaction.

The Micra TPS was awarded CE Mark in April 2015 and U.S. Food and Drug Administration approval in April 2016. It is intended for use in patients who need a single-chamber pacemaker. The Micra TPS is the first and only leadless pacing system, according to Medtronic, to be approved for both 1.5 and 3 Tesla (T) full-body magnetic resonance imaging (MRI) scans, providing patients with access to the most advanced imaging diagnostic procedures available. The device was designed to allow patients to be followed by their physicians and send data remotely via the Medtronic CareLink Network. Remote monitoring of Micra devices is available in Europe and expected to be available in the United States later this year.

For more information: www.medtronic.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Overlay Init